Semi-quantitation of urokinase plasminogen activator and its receptor in breast carcinomas by immunocytochemistry
- PMID: 9635840
- PMCID: PMC2150065
- DOI: 10.1038/bjc.1998.268
Semi-quantitation of urokinase plasminogen activator and its receptor in breast carcinomas by immunocytochemistry
Abstract
Urokinase plasminogen activator (uPA) is a serine protease involved in cancer invasion and metastasis. uPA acts in vivo by binding to a membrane receptor known as uPAR. In this study, uPA and uPAR levels were semiquantitated by immunocytochemistry in 36 primary breast carcinomas. Using monoclonal antibody HD-UK 1, uPA was detected both in stromal and in malignant cells. However, the predominant location was in the stromal cells. Using double-staining, cells containing uPA were also found to coexpress either cytokeratin (an epithelial cell marker) or more frequently KP1 (a macrophage/monocyte cell marker). With monoclonal antibody HD-uPAR 13.1, uPAR was localized principally to spindle- or macrophage-like stromal cells, especially when these cells surrounded invasive breast cancer. In contrast, uPAR was only rarely detected in cancer cells and was not detected in normal epithelia surrounding tumour or in areas of adenosis. uPA levels in both stromal and epithelial cells were significantly correlated with those for uPAR. We conclude that both uPA and its receptor are mostly present in stromal cells in invasive breast carcinomas. These results suggest that stromal cells collaborate with malignant cells to mediate metastasis.
Similar articles
-
Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.Cancer. 1996 Mar 15;77(6):1079-88. doi: 10.1002/(sici)1097-0142(19960315)77:6<1079::aid-cncr12>3.0.co;2-z. Cancer. 1996. PMID: 8635127
-
Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer.Int J Cancer. 1995 May 29;61(5):597-600. doi: 10.1002/ijc.2910610502. Int J Cancer. 1995. PMID: 7768629
-
The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.Int J Oncol. 2009 Jan;34(1):15-23. Int J Oncol. 2009. PMID: 19082473
-
Urokinase receptor variants in tissue and body fluids.Adv Clin Chem. 2007;44:65-102. Adv Clin Chem. 2007. PMID: 17682340 Review.
-
Urokinase-type plasminogen activator system and breast cancer (Review).Oncol Rep. 2005 Jul;14(1):105-12. Oncol Rep. 2005. PMID: 15944776 Review.
Cited by
-
Re-engineering the Immune Response to Metastatic Cancer: Antibody-Recruiting Small Molecules Targeting the Urokinase Receptor.Angew Chem Int Ed Engl. 2016 Mar 7;55(11):3642-6. doi: 10.1002/anie.201510866. Epub 2016 Feb 16. Angew Chem Int Ed Engl. 2016. PMID: 26879524 Free PMC article.
-
Vitamin D3 modulation of plasminogen activator inhibitor type-1 in human breast carcinomas under organ culture.Virchows Arch. 2004 Feb;444(2):175-82. doi: 10.1007/s00428-003-0929-5. Epub 2003 Dec 2. Virchows Arch. 2004. PMID: 14652754
-
The macrophage growth factor CSF-1 in mammary gland development and tumor progression.J Mammary Gland Biol Neoplasia. 2002 Apr;7(2):147-62. doi: 10.1023/a:1020399802795. J Mammary Gland Biol Neoplasia. 2002. PMID: 12465600 Review.
-
Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology.Am J Pathol. 2000 Oct;157(4):1219-27. doi: 10.1016/S0002-9440(10)64637-8. Am J Pathol. 2000. PMID: 11021826 Free PMC article.
-
Tumor-associated soluble uPAR-directed endothelial cell motility and tumor angiogenesis.Oncogenesis. 2013 Jun 24;2(6):e53. doi: 10.1038/oncsis.2013.19. Oncogenesis. 2013. PMID: 23797476 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous